Navigation Links
Amarin Signs Agreement to Acquire Ester Neurosciences
Date:12/5/2007

discoveries in cholinergic neuromodulation. The validation of the platform via the promising clinical data from a Phase II study in myasthenia gravis adds substantial value to Amarin's neuroscience portfolio."

Alan Cooke, President and Chief Financial Officer of Amarin, added, "The Ester acquisition achieves our stated objective of adding one more clinical stage program with efficacy data to our pipeline with the additional benefit of the valuable underlying technology platform. The concurrent financing enables the Company to make the initial $5 million cash payment to Ester shareholders without utilizing the Company's existing cash reserves and provides additional working capital to invest in integrating and advancing Ester's programs along with our existing development pipeline in neurology and cardiovascular disease."

Eli Hazum, Chief Executive Officer of Ester and a partner at Medica Venture Partners, the company founders, commented, "Amarin's experience with neurological disorders and strong management team will be of considerable benefit in advancing our Phase II clinical program in myasthenia gravis and further developing our novel technology platform. We are very excited about the Phase II program as the interim results have demonstrated superior efficacy over MestinonTM, the current standard of care for this disease."

Nava Swersky Sofer, President and Chief Executive Officer of Yissum, the Hebrew University of Jerusalem's technology transfer company, from which Ester licensed the technology, commented, "This technology, developed by Professor Hermona Soreq, has the potential to aid numerous patients around the world suffering from debilitating chronic diseases. Ester has developed the technology over the past ten years, and we are delighted that Amarin has decided to take it to the next level using its considerable strengths and excellent team."

EN101 in Phase IIa for Myasthenia Gravis

Ester's lead product candidate, EN10
'/>"/>

SOURCE Amarin Corporation Plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
2. Amarin to Present at 4th Annual Bio Investor Forum
3. Amarin Announces Initiation of Cardiovascular Development Strategy
4. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
5. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
6. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
7. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
8. Monsanto Company Signs Share Subscription Agreement With Devgen
9. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
10. Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company
11. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 /PRNewswire-iReach/ -- Researchers found that ActiveLife Scientific,s ... with bone fragility fracture when today,s standard bone ... are at risk of fracture for reasons that ... test, the DEXA bone density scan.  Study results ... and Mineral Research Annual Conference (ASBMR) in ...
(Date:9/16/2014)... 2014 RENU 28, the world's first and ... available for purchase in Australia and New Zealand in mid-August ... September 16th. The tour will make stops in Brisbane on ... the 18th, Sydney on the 20th, and Melbourne on the ... New Zealand and to educate people about the new product ...
(Date:9/15/2014)... Sept. 15, 2014  FlexTech Alliance today issued ... printed product demonstrators (demos) and a functional electronic ... with pre-proposals due on October 22, 2014 and ... proposals ultimately selected are provided by the US ... cost share by the proposing organization. ...
(Date:9/15/2014)... NC (PRWEB) September 15, 2014 ... developed deep imaging OCT system for the optical device ... The EnvisuTM S4410 SDOCT for Contact Lens ... for standard and high complexity contact lens, IOL structures, ... imaging of a complete contact lens immersed in a ...
Breaking Biology Technology:ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 2ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 3Global Wellness Company Hosts ASEA Australia Tour September 16-22 2FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2
... , , , ... ) announced that it will be hosting a conference call to discuss today,s ... begin at 8:30 a.m. Eastern Time (ET)/5:30 a.m. Pacific Time (PT). , ... accessed through a link that is posted on the home page of Nektar,s ...
... ... firms have to follow a rigorous documentation process to comply with a ... corporate agreements these firms are faced with the daunting task of sharing ... affordable unlimited use facility to share thousands of confidential documents securely and ...
... question, researchers with the U.S. Department of Energy,s ... that the selective placement of strain can alter ... correlated electron materials. This unique class of materials ... display properties such as colossal magnetoresistance and high-temperature ...
Cached Biology Technology:Nektar Therapeutics to Host Conference Call to Discuss Today's Announcement of a New Partnership for NKTR-118 and NKTR-119 2Life Science Firms are Turning to Firmex to do Deals Online 2Life Science Firms are Turning to Firmex to do Deals Online 3Strain on nanocrystals could yield colossal results 2Strain on nanocrystals could yield colossal results 3
(Date:9/15/2014)... gut microbes influence processes from digestion to disease resistance. ... biodiverse terrestrial ecosystems on the planet, more is known ... tropics. Smithsonian scientists and colleagues working on Panama,s Barro ... single tree were home to more than 400 different ... species contained more than 7,000 different kinds. , Bacteria ...
(Date:9/15/2014)... a morphine regimen can result in better pain control ... the dosage of the opioid needed to be effective, ... University. , The result could bring significant relief to ... felt in the arms and legs and associated with ... need for better treatments for neuropathic pain," said Fletcher ...
(Date:9/15/2014)... print issue of the journal Science comes ... Mexico, Montana and even the Netherlands, thanks to the ... the norm in these connected times. Yes, the research ... innovations in biology, medicine, biotechnology and agriculture. It could ... with that one, that one knew another one, and ...
Breaking Biology News(10 mins):Smithsonian scientists discover tropical tree microbiome in Panama 2IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2Collaboration drives achievement in protein structure research 2
... early bird rates for the premier bone meeting in 2012. ... 21-24, 2012 will be held in in the magnificent city ... register by December 9, 2011 at http://www.iof-ecceo12.org ... key thought leaders... Plenary lectures:, The conundrum ...
... now possible to use dental X-rays to predict who is ... at the Sahlgrenska Academy reported in the journal Nature ... the University of Gothenburg,s Sahlgrenska Academy and Region Vstra Gtaland ... in the lower jaw is linked to a greater chance ...
... and more solar modules are appearing on rooftops, and ... into the grid. Multi-junction solar cells are particularly efficient ... to 43 percent - twice the level of conventional ... consist of several semi-conductor layers that combine to transform ...
Cached Biology News:Register now for the European Congress on Osteoporosis & Osteoarthritis in Bordeaux 2Dental X-rays can predict fractures 2Fraunhofer researchers receive the Franco-German Business Award 2011 2
... Dinitro-5,5'-dithiodibenzoic acid , DTNB , Ellman's reagent ... , *CAS-No.: 69-78-3 *Storage: ... with a reactive grouping not present in the ... reagent which will react directly with the product ...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
... RNase Inhibitor (patent pending) is a protein ... binds and inhibits the most common and ... 1 and T1. SUPERaseIn can be used ... be problematic. It is ideal for in ...
... Recombinant Ribonuclease Inhibitor is a ... ribonucleases such as RNase A. ... Recombinant Ribonuclease Inhibitor is an ... weight ~52 kDa. RNaseOUT inhibits ...
Biology Products: